Society of Diabetic Nephropathy Prevention Journal of Nephropathology 2251-8363 12 4 2023 09 19 Advances in IgA nephropathy management, from pathological insights to personalized treatment e21480 e21480 10.34172/jnp.2023.21480 EN Mitra Shavakhi https://orcid.org/0000-0003-0719-0786 Agha Wajdan Baqir https://orcid.org/0000-0002-1158-8896 Journal Article 10.34172/jnp.2023.21480 2023 04 26 2023 06 21 IgA nephropathy is a common glomerulonephritis with variable clinical outcomes. The optimal treatment for this condition remains uncertain, and corticosteroid therapy is reserved for patients unresponsive to supportive treatment. The histopathologic examination has a significant role in the diagnosis and prognosis of IgA nephropathy, but its role in the initiation of corticosteroid therapy is still under debate. Recently, targeted release formulation (TRF)-budesonide has emerged as a promising treatment due to its localized delivery to the gut and low systemic adverse effects. This brief review aims to assess recent advancements in IgA nephropathy management, focusing on applying Oxford classification in guiding corticosteroid therapy.